Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Haioun, C.
Right arrow Articles by Reyes, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haioun, C.
Right arrow Articles by Reyes, F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 12:1749-1755, 2001
© 2001 European Society for Medical Oncology

research-article

Tandem autotransplant as first-line consolidative treatment in poor-risk aggressive lymphoma: A pilot study of 36 patients

C. Haioun1,, N. Mounier2, B. Quesnel3, P. Morel4, C. Rieux1, F. Beaujean1, J.-P. Marolleau2, K. Belhadj1, D. Simon2, Ph. Gaulard1, E. Lepage1, Ch. Gisselbrecht2 and F. Reyes1

1Hôpital Henri Mondor Créteil
2Hôpital Saint-Louis Paris
3Centre Hospitalier Huriez Lille
4Centre Hospitaher Schaffner Lens, France

C Haioun, MD, Service d'Hématologie Clinique, Hopital Henri Mondor, 51 Avenue du Maréchal de Lattre deTassigny, 94010 Créteil, France, E-mail: corinne.haioun{at}hmn.ap-hop-paris.fr

Purpose: In the previous LNH87-2 study, consolidative high-dose therapy followed by stem cell transplantation (HDT) improved disease-free survival, as well as survival for patients (pts) presenting with two or three factors of the age-adjusted international prognostic index (Aa-IPI) in first complete remission (CR). In order to improve further the outcome of such patients, we conducted a pilot study of consolidative tandem autotranplant.

Patients and methods: Thirty-six patients (pts) under 60 years of age with two or three factors of the Aa-IPI were enrolled. Their main characteristics were: diffuse large B-cell lymphoma (83%), Aa-IPI three factors (50%), and marrow involved (36)%. The procedure consisted of 1) induction with four cycles of ACVBP (doxorubicin, cyclophosphamide, vin-desine, bleomycin, prednisone) 2) in responding pts, peripheral blood stem cell (PBSC) collection after the fourth cycle of ACVBP (11 pts) or after an additional mobilization regimen (Cyclophosphamide - VP16) (17 pts) 3) a first HDT (mitoxan-trone, cyclophosphamide, VP16 and carmustine) followed by PBSC infusion 4) a second HDT (busulfan, carboplatin and melphalan) followed by PBSC infusion. Among the 29 patients responding to induction, 28 received the first HDT and 24 the second.

Results: The rates of three-year-event free survival and survival are 47% (95% confidence interval (95% Cl: 31%63%) and 50% (95% Cl: 37%–69%), respectively. Eighteen patients remained free of evolutive disease and 18 patients have died, 15 from disease progression and three from treatment-related toxicity after tandem transplant (two veno-occlu-sive disease and one cerebral toxoplasmosis).

Conclusion: We conclude that tandem transplant did not improve the results of the LNH87-2 study in which patients received a single consolidative HDT.

autotransplant, non-Hodgkin's lymphoma, tandem


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.